Company intelligence / Profile preview

Shenyang Enshi Pharmaceutical

Shenyang, Liaoning, China

Ownership: Private
Employees: ~2426
Development stage: Other

Overview

Multiple ophthalmic drugs approved by NMPA, including Tafluprost Eye Drops (Jan 2025), Olopatadine Hydrochloride Eye Drops, Bromfenac Sodium Eye Drops, Atropine Sulfate Eye Drops for myopia, and others for anti-infective, anti-inflammatory, and anti-glaucoma uses.

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shenyang Enshi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenyang Enshi Pharmaceutical.

Explore the full profile